Neonatal thymectomy (NTX) of BALB/c mice between days 1 and 3 post-birth leads to a high incidence of autoimmune gastritis involving T cells and autoantibodies. Although progress has been made in understanding various immunological events associated with that disease process, much remains to be learned about the regulatory factors which control autoimmune gastritis. In this study we have examined the potential for neuroendocrine hormones of the hypothalamuspituitary-thyroid (HPT) axis to alter the outcome of experimental autoimmune gastritis in NTX mice. As reported here, thyroxine administered to young adult NTX mice during an active phase of disease development dramatically reduced the incidence of gastritis and the overall severity of disease, and lowered the levels of anti-parietal cell antibodies. In contrast, treatment of young NTX mice with thyroxine or other HPT hormones prior to the onset of disease had no beneficial effect on gastritis, but instead resulted in significantly higher anti-parietal cell antibody levels compared to non-hormone-treated NTX mice or to NTX mice treated as adults. Reverse transcriptase spectratype analyses of 22 V β gene junctional sites revealed pronounced oligoclonality and limited junctional diversity in stomach lymphocytes from untreated NTX mice compared to normal mice or thyroxine-treated NTX mice. These findings identify a set of dynamic immune-endocrine interactions, linked to critical development-dependent events, that are involved in the expression and regulation of peripheral autoimmunity.
The extent to which the maintenance of immune tolerance to self is controlled during T cell development or is regulated in the periphery, or is a combination of both, is central to gaining a comprehensive understanding of the autoimmune disease process. Experimentally, organ-specific autoimmune diseases, including autoimmune gastritis involving both T cell responses and autoantibodies, can be elicited in mice following thymectomy between days 1-3 post-birth (1) (2) (3) (4) . However, because autoimmune gastritis is rare in congenitally athymic nude mice and in mice thymectomized after day 6 of birth, there appears to be an important developmental window during which the immune system can be rendered vulnerable to subsequent autoimmunity. In humans, autoimmune gastritis is characterized by inflammation and atrophy of the mucosa in the body of the stomach, loss of parietal cells and chief cells, autoantibodies to the parietal cell H ϩ K ϩ -ATPase and the intrinsic factor, and is responsible for achlorhydria, vitamin B12 deficiency and megaloblastic anemia (5).
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Transmitting editor: C. B. Thompson Received 30 July 1997, accepted 10 October 1997 This may occur alone or as part of type II polyendocrine autoimmunity. In addition, an association is known to exist between autoimmune thyroiditis and autoimmune gastritis in that many patients with autoimmune thyroiditis have circulating antibodies to gastric parietal cells (6) . The interdependence of the immune system and hormones of the hypothalamus-pituitary-thyroid (HPT) axis is well documented (reviewed in 7). These include bidirectional responses involving a variety of immunologically important cytokines such as IL-1 (8), IL-6 (9), IFN-γ and tumor necrosis factor (TNF)-α (10), which can influence the development and growth of the thymus (11, 12) and affect antibody-mediated responses (13) . Moreover, there is longstanding evidence demonstrating that disruption of either the immune system or the endocrine system during critical developmental periods of fetal/neonatal life leads to physiological perturbations in the other process (14, 15) . HPT hormones also have been shown to alter the distribution and numbers of T cells in mucosal tissues. Thus, thyrotropin-releasing hormone (TRH) and thyrotropin [i.e. thyroid-stimulating hormone (TSH)] given to young adult neonatally thymectomized (NTX) mice results in an increase in the number of TCRαβ, CD8αβ T cells in the small intestine epithelium (16, 17) , whereas treatment of normal euthymic mice with thyroxine results in a decrease in those T cell populations (18) . Interestingly, TRH or TSH treatment of congenitally athymic nude mice has minimal effect on mucosal T cells (16) , once again suggesting a temporal relationship between the developing thymus and, in this case, Note that although the incidence of disease was first apparent between weeks 3-4 post-birth, severity of gastritis did not reach maximal levels until after 7 weeks of age and was statistically less severe between those two points (P Ͻ 0.01) as determined by Student's t-test for unpaired observations. Number of mice per group: week 1-2, N ϭ 9; week 3-4, N ϭ 17; week 5-6, N ϭ 20; week 7-12; N ϭ 7; week Ͼ12, N ϭ 8. BALB/c mice were raised at the University of Tulsa vivarium from breeding stocks obtained from The Jackson Laboratory (Bar, Harbor, ME). NTX mice were prepared as previously described (16, 17) using standard protocols (25) . Stomach tissues were fixed in Bouin's fixative and embedded in paraffin. Five-micron thick sections were stained with hematoxylin & eosin and coded specimens were scored for disease using four parameters (parietal cell loss, hyperplasia, gastritis and extensiveness of disease throughout tissues). Each parameter was rated on a scale of 0 to 3 and the values from each category were averaged for an overall grade. The disease severity index for each group was calculated using the overall grade per mouse as follows: [ the endocrine system as it pertains to mucosal immune homeostasis. Based on those observations, we have examined the potential for neuroendocrine hormones of the HPT axis to influence the outcome of autoimmunity within the gastrointestinal tract using the experimental autoimmune gastritis model in NTX mice.
To determine the time of disease onset in NTX mice, histopathological analyses were done on stomach tissues from groups of NTX mice at weekly intervals post-thymectomy. As shown in Fig. 1(A) , gastritis could be detected in some NTX mice as early as 3-4 weeks of age, although there was a progressive increase in the incidence of disease until 7 weeks of age. However, gastritis in NTX mice was significantly less severe up to 6 weeks of age than in NTX mice after 6 weeks (Fig. 1B) . Therefore, two schedules of hormone treatment were used in this study. The first consisted of NTX mice treated with HPT hormones beginning 24 h post-thymectomy. The rationale for this was based on observations that neonatal thymectomy may alter regulatory T cell components involved in the control of autoimmunity (1) (2) (3) (4) and that early hormone treatment might directly or indirectly influence those cell populations. The second treatment schedule consisted of NTX mice given HPT hormones beginning at 6 weeks of age. The rationale for this was based on the findings described above regarding the time of disease onset and on studies indicating that the administration of HPT hormones to NTX mice at 6 weeks of age can significantly change the composition of T cell subsets present within mucosal tissues (16) (17) (18) .
A total of 153 NTX BALB/c mice consisting of 46.9% male mice and 53.1% female mice comprised eight groups. Three groups were treated with TRH, TSH or thyroxine as neonates; three groups were treated with TRH, TSH or thyroxine as adults at 6 weeks of age; a group of NTX mice was left untreated; and a group consisted of normal, untreated, nonthymectomized mice (Table 1) . Hormones were given for 3 weeks according to previous treatment schedules (16) (17) (18) . Mice were sacrificed at 9-12 weeks of age, sera were collected and stomach tissues were prepared for blinded histopathological analyses. The incidence of gastritis in untreated NTX control mice (52.6%) was consistent with what has been reported in other studies of autoimmune gastritis in BALB/c NTX mice (1); no gastritis was present in normal, Note that the incidence of gastritis is significantly lower in thyroxine-treated adult NTX mice compared to NTX mice treated with hormones as neonates or untreated NTX mice and is similar to that observed for untreated NTX mice at 5-6 weeks of age (Fig. 1B) . Hormone treatment of NTX mice was done according to previously published protocols (16) (17) (18) . Treatment consisted of daily i.p. injection (5 µg/g body wt) of TRH (p-Glu-His-Pro amide) (Sigma, St Louis, MO) or TSH (Sigma) for 5 days followed by six injections of TRH or TSH given every third day thereafter. Thyroxine (Sigma) (0. 35 µg/g body wt) was given daily for 5 days followed by a 2 day rest, for a total of 3 weeks. U ϭ untreated NTX mice.
untreated, thymus-bearing animals ( Table 1 and Fig. 2A ). Histopathologic analyses of stomach tissue sections revealed features in diseased mice typical of autoimmune gastritis (1) (Fig. 2B) .
NTX mice treated with either TRH, TSH or thyroxine as neonates had an incidence of gastritis equivalent to, and statistically no different from, non-treated NTX control mice (47.0-57.1%) ( Table 1 and Fig. 2C ). That pattern also held true for NTX mice treated with TRH or TSH at 6 weeks of age (Table 1) . Most interesting, however, was the finding that NTX mice treated with thyroxine at 6 weeks of age had a significantly lower incidence of autoimmune gastritis (16.7%) compared to untreated mice (Table 1) . Reduction in disease occurred in both female and male thyroxine-treated mice: from 60% (12 of 20 mice with disease) in untreated females to 23% (three of 13 mice with disease) in thyroxine-treated females, and from 44% (eight of 18 mice with disease) in untreated males to 0% (none of five mice with disease) in thyroxine-treated male mice (Fig. 3A) .
To evaluate the extent to which hormone treatment could modulate the overall severity of disease, rather than just the presence or absence of disease, disease severity indices were determined from histopathological analyses of stomach tissues for each animal group. Shown in Fig. 3(B) , the severity of disease among NTX mice treated with TRH, TSH or thyroxine as neonates was equivalent to that of untreated mice, indicating that hormone treatment of neonatal NTX mice as neonates had no modulating effect on the disease process. However, treatment of adult mice with thyroxine during the time of disease progression resulted in an overall milder form of disease (Fig. 2D) . The disease severity index (0.33) of 9-to 12-week-old NTX mice treated for 3 weeks beginning at 6 weeks of age (Fig. 3B ) was equivalent to that (0.31) of untreated NTX mice at 5-6 weeks of age, i.e. at the time when disease was not yet fully expressed in untreated NTX mice (Fig. 1B) , suggesting that the effect of thyroxine may be to arrest or terminate the disease process when given at that point.
Because the presence of anti-parietal cell antibodies is linked to the expression of autoimmune gastritis (2-4), antiparietal cell antibody levels were measured in hormonetreated mice and control mice. All three groups of NTX mice given hormones as neonates had an increase in anti-parietal antibody levels, the most dramatic of this being a statistically significant increase (P ϭ 0.014) in anti-parietal cell antibody titers of NTX mice treated with thyroxine as neonates compared to untreated NTX mice (Fig. 4) . In contrast, there was a slight reduction in antibody levels in TSH-and thyroxinetreated adult NTX mice compared to untreated NTX mice. Most significant, however, was the finding that anti-parietal cell antibody levels in NTX mice treated with TSH or thyroxine as adults were markedly lower (P Ͻ 0.05) than antibody levels in NTX mice treated with those hormones as neonates (Fig.  4) . These findings indicate that thyroxine has the potential to actively influence the autoimmune antibody response, and they demonstrate that those outcomes are co-dependent events which involve the age of the animal at the time of hormone exposure and the time at which disease onset occurs.
Finally, to study the involvement of T cells to the expression of autoimmune gastritis in the context of hormone treatment, RT-PCR spectratype analyses were done for 22 TCR V β genes using stomach lymphocytes from normal euthymic mice, untreated NTX mice with disease and thyroxine-treated NTX mice. In normal euthymic mice, V β rearrangements were evident for approximately two-thirds of the V β genes examined, most of which expressed considerable polyclonality with the VDJ junctional region (Fig. 5, top) . In stomach lymphocytes from untreated mice, similar combinatorial diversity was observed, though with a high degree of V β oligoclonality (Fig. Fig. 4 . Comparison of anti-parietal cell antibody levels of hormonetreated and untreated mice (mean values Ϯ SEM). Antibody levels of NTX mice treated with thyroxine as neonates were significantly greater (p ϭ 0. 014) than antibody levels of non-hormone-treated NTX mice (o ∫ ). Antibody levels of NTX mice treated with TSH (Φ) or thyroxine (#) as neonates were statistically greater than antibody levels of NTX mice treated with TSH or thyroxine as adults (P Ͻ 0.05) as determined by Student's t-test for unpaired observations. Antiparietal cell antibody assays were done using published protocols (26) . U ϭ untreated NTX mice.
5, middle). Of interest, however, was the finding that NTX mice treated with thyroxine as adults had spectratype patterns, including the degree of polyclonality among rearranged V β genes, that were similar to those of normal mice (Fig. 5,  bottom) . These findings suggest that the TCRαβ repertoire in autoimmune gastrities is skewed towards a few dominant V β specificities which presumably reflect distinct antigen reactivities of the inflammatory cell pool and that this shift can be modulated by thyroxine treatment.
The findings reported here establish a link between the thyroid hormone and the regulation of experimental autoimmune disease in mice. In addition to the overall reduction in disease and disease severity by thyroxine, an unexpected finding of this study was the differential regulation of antiparietal cell antibody responses as a function of the type of hormone (principally TSH and thyroxine), the age of the animal and the status of the disease. While the mechanistic basis for those interaction remain to be elucidated, there are several potential ways by which the effects of thyroid hormone could be manifest. It is possible that thyroxine down-regulates autoreactive lymphocytes which otherwise would have been suppressed during normal T cell development (18) . This scenario is consistent with the capacity of thyroxine to selectively alter the distribution and proportion of lymphocytes in other regions of the gastrointestinal mucosa (19, 20) or by local immune regulation via the mucosal epithelium (21) . Alteratively, the effect of thyroxine may be to modulate functional properties of existing T cells rather than to cause a change in cell populations. Such qualitative effects could be achieved by modifying cytokine secretion profiles or by altering lymphocyte migration patterns. Indeed, hormones and neuropeptides can cause an influx of leukocytes into tissue spaces (22) . It is also possible that thyroxine acts locally in the stomach by reducing the susceptibility of the target organ to autoimmune disease (23) ; in this case, disease RT-PCR-spectratype analyses of 22 V β genes in lymphocytes isolated from the stomach of a normal 10-week-old euthymic mouse (top panel), an untreated 9-week-old NTX mouse (middle panel) and a 9-week-old NTX mouse treated with thyroxine as an adult (bottom panel). Note the pronounced oligoclonality of V β rearrangements in T cells from untreated NTX mice compared to normal mice and thyroxine-treated animals. Lymphocytes from stomach tissues were isolated using protocols for intestinal lymphocytes (27) . Total cellular RNAs were extracted using Trizol (BRL, Gaithersburg, MD) and cDNAs were made as previously described (28) . TCRβ genes were amplified across the VDJ junctional site using a V β upstream primer and a 32 P-end-labeled C β downstream primer (28, 29) . PCR products were electrophoresed through a 6% acrylamide sequencing gel, followed by overnight exposure to radiographic film (Amersham, Arlington Heights, IL) prior to developing. resistance may be conferred by selectively altering target antigens or by enhanced local immunoregulation in the gastric mucosa. The latter is feasible in the light of recent findings of a thyrotropin-mediated network of endogenous hormone production and utilization within the intestinal mucosa (24) , and by the fact that the reduction in gastritis incidence in thyroxine-treated mice in the present study was not associated with a significant reduction in oophoritis in HPT hormonetreated animals (data not shown), thus implying differential levels of hormone-mediated immune regulation throughout peripheral tissues.
Taken together, these possibilities also may explain why in the present study both TSH and thyroxine lowered antiparietal cell antibody levels in NTX mice, yet only thyroxine had a significant modulating effect on gastritis. Considering the likely participation of TCRαβ T cells in the inflammatory process at the level of the stomach mucosa itself (Fig. 5) , it is possible that although TSH and thyroxine act along the same physiological axis, each is targeted to distinct lymphocyte populations involved in separate aspects of the disease process. Consequently, these effects would not be evident in most prior studies of experimental autoimmune gastritis.
The beneficial effects of thyroxine when given to mice during a period of active disease development suggests that this hormone may have potential therapeutic use in the treatment of autoimmune gastritis and implies that deficiencies in thyroid hormone may be an important trigger for that disease. Whether there is a link between the high concordance rate between autoimmune thyroiditis and autoimmune gastritis in humans cannot be determined from the present study; however, further investigation into that possibility is warranted. Similarly, kinetic studies examining thyroxine levels in NTX mice up to the time of disease onset may prove useful for further understanding the temporal relationship between thyroxine and autoimmune gastritis. Regardless, the findings reported here indicate that elucidating factors which control immune homeostasis and autoimmune disease pathogenesis are more intricate than previously envisioned, and will necessitate analyses of biological processes that extend beyond classical notions of immune regulation.
